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Thyroid dysfunction in the
elderly
G M M Muller, N S Levitl, S J Louw
Objectives. To determine the prevalence of thyroid
dysfunction in institutionalised elderly people in Cape
Town and to assess the usefulness of an abnormal
thyroid-stimulating hormone (TSH) concentration as a
screening test in this group.
Design. Cross-sectional survey.
Setting. Four Old-age homes in Cape Town.
Subjects. Old-age home residents aged 60 years and
over.
Outcome measures. Serum concentrations of TSH, tree
thyroxine and free tri-iodothyronine.
Results. Serum TSH estimations were performed on 658
participants, and were abnormal in 103 (15.6%) - 41
(6.2%) being elevated (> 5.0 ~U/ml) and 62 (9.4%) being
low « 0.4 IJU/ml). There were 3 newly diagnosed cases of
hyperthyroidism and 7 of hypothyroidism. Subclinical
disease was diagnosed in 40 subjects. The overall
prevalence of thyroid dysfunction in this population was
11.2%. In 22 (3.4%) this had previously been recognised,
while in 50 (7.8%) the dysfunction was newly diagnosed
by the current survey. The positive predictive value of a
TSH concentration> 20 jJU/ml in predicting
hypothyroidism is 67%, while it will predict 100% of cases
of subclinical hypothyroidism. A TSH concentration
< 0.1 ~U/ml will predict 23% of cases of hyperthyroidism,
but 81 % of cases of subclinical disease.
Conclusions. The prevalence of thyroid dysfunction in
institutionalised elderly people in Cape Town is similar to
that reported for elderly people in other centres. Thyroid
dysfunction had not previously been recognised in
approximately two-thirds of the subjects in this study. The
serum TSH concentration is a reliable screening test for
thyroid dysfunction in the elderly, but is less useful if used
to identify biochemical thyroid disease. An elevated TSH
concentration is a better predictor of thyroid dysfunction
in the elderly than a depressed TSH concentration.
S Afr Med J 1997: 87: 1119-1123.
Thyroid disease may manifest atypically in the elderly,
leading to difficulties with clinical diagnosis. I .2 There are well
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recognised alterations in thyroid physiology which occur
during normal ageing.3-!i Both iodine uptake by the gland and
thyroxine (fJ production decrease. As a result of decreased
peripheral metabolism, however, serum levels of T~ remain
normal. Diminished S'-deiodinase activity results in
decreased conversion of T~ to tri-iodothyronine {TJ and
slightly lower serum T3 levels.
Several reports have suggested that thyroid dysfunction is
more common in older subjects, 1.~.'; but the exact prevalence
has been difficult to determine. The clinical diagnosis of
both hypo- and hyperthyroidism may be obscured by the
fact that their clinical features are often incorrectly attributed
to ageing per se. In addition, the lack of uniformity in
laboratory techniques has resulted in reported prevalence
rates that are not strictly comparable.
The general availability of sensitive thyroid-stimulating
hormone (TSH) assays able to measure very low levels has
resulted in the use of TSH as a screening test for
hyperthyroidism as well as hypothyroidism. Its utility seems
to be well established in young subjects, but its value as a
marker of thyroid dysfunction in the elderly is unproven.
The present study was undertaken with the following
aims: (I) to determine the prevalence of thyroid dysfunction
in institutionalised elderly in Cape Town; and (it) to assess
the usefulness of an abnormal TSH concentration as a
screening test in this group.
Subjects and methods
The residents of four old-age homes who were aged 60
years and older were invited to participate in the study. The
only exclusions were those residents who refused to take
part and those from whom venous blood could not readily
be obtained. After written consent had been obtained,
questionnaires were completed by trained nursing and
medical staff. These contained baseline demographic data
as well as health status data, including previous or current
medical or thyroid problems and current therapy. Blood was
taken for serum TSH estimation. After separation of the
serum, it was stored at -20DC. TSH concentrations were
measured with the Gamma-BCT TSH method
(Immunodiagnostic Systems, Boldon, Tyne & Wear, UK). The
normal range for this laboratory is 0.4 - 4 IJU/ml. However,
we used 5 IJU/ml as the upper limit of normal in this study, in
line with a recent published series using the same
technique. In patients whose initial TSH concentration fell
outside the range 0.4 - 5 IJU/ml, a second sample was
drawn and the TSH measurement repeated together with
estimations of the serum free T, (FT) and free T, (FTJ
concentrations (Amer1ex-M AlA method, Kodak Clinical
Diagnostics Ltd, Amersham, UK). The normal range for FT...
was 6.3 - 22.8 pmolll, while that for FT3 was 3.3 - 8.1 pmotll.
Subjects with clear biochemical evidence of thyrotoxicosis
or hypothyroidism were referred for appropriate treatment.
After a further 6 months, TSH, FT~ and FT3 estimations
were repeated in all who had had an abnormal baseline TSH
level.
Approval for the stUdy was obtained from the UCT Ethics
and Research Committee, as well as from the Chairman of
the Cape Peninsula Organisation for the Aged and from the
doctors involved in providing medical care for these
residents. Confidentiality was ensured, and abnormal
findings were passed on to each patient's doctor.
Definitions
'Thyroid dysfunction' encompassed previously diagnosed
hyperfunction or hypofunction, previous thyroidectomy (for
whatever reason), newly diagnosed thyrotoxicosis or
hypothyroidism and subclinical thyroid disease. Those with
the sick euthyroid syndrome and the single participant with
a transient elevation of FT3 were not considered to have
thyroid dysfunction.
'Hypothyroidism (overt)' was present in patients with
previously diagnosed thyroid hypofunction, as well as those
in the present study whose initial and subsequent TSH
levels were elevated, and who had depression of FT....
'Subclinical hypothyroidism' was present in patients with
no overt clinical features of hypothyroidism, but elevated
TSH levels and normal FT.. and FT) levels. In this study this
included those whose initial and subsequent TSH levels
were elevated but who had normal FT... levels.
'Thyrotoxicosis (overt)' was characterised by elevated
thyrOXine levels with depression of the TSH. This includes
those in whom both the initial and subsequent TSH levels
were depressed, and who had elevation of FT....
'Subclinical hyperthyroidism' was characterised by an
absence of clinical features of hyperthyroidism, but low TSH
levels with normal FT., and FT) levels. It included those
patients whose initial and repeat TSH levels were depressed
but who had normal FT~ and FT3 levels. The TSH depression
was frequently transient, later returning to normal.
'Sick euthyroid syndrome' entailed depression of the TSH
level in individuals who were euthyroid as evidenced by
normal FT... levels, but who had non-thyroidal illness, stress
or physical trauma. For the purposes of this study, the sick
euthyroid syndrome was diagnosed in those whose initial
TSH was low and who had a depressed Ts with a normal or
low TSH level on repeat estimation.
Results
There were 658 participants, aged between 60 and 98 years
(mean age 77.9 years). Of these, 169 were male (25.7%) and
489 were female (74.3%). The participation rate was high,
with 86% of the 776 residents in the 4 old-age homes taking
part. The reasons for non-participation were that the
resident was too young « 60 years) or refused consent, or
that a blood specimen could not be obtained.
One hundred and three (15.6%) of the initiai 658 serum
TSH estimations were abnormal (Fig. 1). These included 41
(6.2%) subjects with elevated TSH levels (> 5.0 ~U/ml) and
62 (9.4%) with low TSH leveis « 0.4 ~U/ml). The serum TSH
concentration was normal in the remaining 555 (84.3%).
TSH estimations were repeated together with measurement
of FT~ and FTs concentrations in 85 of the original 103
subjects with abnormal TSH levels, the remaining 18 having
died in the interim. The denominator for further calculations
was therefore 640.
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555 (84.3%) NORMAL
658/
~ /41 (6.2%) ELEVATED
103 (15.6%) ABNORMAL~




Fig. 1. Initial TSH estimations.
commenced therapy with thyroxine. A further 2 subjects
were previously known to be hypothyroid. One was receiving
inadequate replacement and was biochemically hypothyroid,
while the other had a normal FT. level. Of the 15 patients
with subclinical hypothyroidism, 13 survived 1 year and, on
retesting, none had progressed to biochemical
hypothyroidism.
There were 62 participants with depressed TSH
concentrations « 0.4 ~U/ml) of whom 5 were thyrotoxic.
This was newly diagnosed in 3, while in the other 2 subjects
excess thyroxine replacement was the cause (Table 11).
Subclinical hyperthyroidism (Iow TSH but normal FT~ and FT3
levels) was noted in 25 subjects. This was transient in 10 as
thyroid function normalised on repeat testing.
Initial TSH
Table 11. Outcome in subjects whose initial TSH level was
abnormal
• These groups each conta:in 1 subject who was Ihyrotoxic as a result of excess
administered thyroxine. and are added to the 3 with newty diagnosed thyrotoxicosis
to give a total of 5 patientS found to be hyperthyroid.
The sick euthyroid syndrome was present in 13 subjects.
The initial TSH level was depressed in all but 1, in whom it
was elevated. This subject later developed depressed TSH
and T3 levels, dying soon thereafter of carcinoma of the lung.
Elevation of T3 was noted in 1 subject, but this was
transienl These latter 2 groups were not considered to have
thyroid dysfunction.
Many participants were on medications which are known






























Hyperthyroidism 2 3 5
Subclinical hyperthyroidism 25 25
Hypothyroidism 11 7 18
Subclinical hypothyroidism 15 15
Surgery 9 9
- -
Total (%) 22 (3.4) 50 (7.8) 72 (11.2)
Table I. Thyroid dysfunction - previously recognised and newly
diagnosed
The serum TSH concentration was found to be > 5 ~U/ml
in 41 subjects (Table 11). Seven subjects had newly
diagnosed hypothyroidism with depressed FT~ levels and
On repeat testing, the TSH level was found to have
reverted to normal in 13 participants. In 9 of these it had
previously been elevated, while in 4 it had been depressed.
The overall prevalence of thyroid dysfunction was 11.2%
(72/640) (Table I). In 22 (3.4%) this had been previously
recognised, while in 50 (7.8%) the dysfunction was newly
identified by the current survey. (It should be noted that
some subjects with previously diagnosed thyroid
dysfunCtion had normal TSH levels during this study, while
some whose initial TSH was abnormal when surveyed were
subsequently shown to be euthyroid.) All but 2 of the 10
subjects with newly recognised overt thyroid disease were
women, both men having neWly diagnosed hypothyroidism.
There were 6 men with subclinical hyperthyroidism.
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repeat Hypothyroid hypothyroid Hyperthyroid hyperthyroid syndrome TJ toxicity
2 2
1 1








SAMJ Volum~Si 1"0. 9 Sepr~mber 1997 1121
Table IV. Positive predictive value of elevated TSH levels
Positive predictive value (%) for. < 0.4 < 0.15 < 0.1 0
Discussion
It was not possible to determine the sensitivity or
specificity of TSH as a screening test for thyroid dysfunction
since participants with normal TSH values were not
assessed further.
than elderly people living in the community, and therefore
more likely to have non-thyroidal illness or to be on
medications which could influence their TSH levels.
As a normal serum TSH level excludes hyperthyroidism or
hypothyroidism for practical purposes,~ in this study only
those participants with abnormal TSH results were
subjected to additional investigations; the remainder were
considered to have normal thyroid function.
Our finding that 15.6% of the initial TSH estimations were
outside the normal range is similar to the result of 13.8%
obtained by Parle et al. in their recent study.s However, in the
latter study all patients on thyroxine therapy were excluded.
If those in our study who were on thyroxine are excluded,
the overall prevalence of abnormal TSH concentrations is
14.9%.
The 6.2% prevalence of elevated TSH levels in this study
is slightly lower than the 7.9% reported by Parle et al. and
the 10.3% of Sawin et al., both of whom used a TSH level
> 5 IJU/ml as their cut-off value.6.1
In this study 7 of the 41 (17.1%) subjects with an
increased TSH level were found to be hypothyroid, giving a
prevalence of newly diagnosed hypothyroidism of 1.1 %
(7/640). Parle et al. report that 18 of 94 (19.1 %) with an
elevated TSH level were hypothyroid (1.5% overall), as
compared with 2.5% in the Sawin study.6.1
Subclinical hypothyroidism was diagnosed in 15 patients,
giving a prevalence of 2.4% in subjects not on thyroxine.
The prevalence rates in other reported studies have been
somewhat higher. Parle et al. had a prevalence of 6.1 %,
while in the study by Sawin et al. the figure was 7.1 %.u In
the report by the latter group it was not clear how many of
the SUbjects in their study population were on thyroid
replacement.
In contrast to the report by Parle et al., in which 17.8% of
their patients with subclinical hypothyroidism progressed to
hypothyroidism within a year, none of the 13 subjects in this
study developed biochemical evidence of overt
hypothyroidism when followed up for a similar period.s Parle
et al. noted that progression was more likely in those where
the initial TSH level was greater than 10 IJU/ml and in those
with positive antithyroid antibodies. Antithyroid antibodies
were not evaluated in the present study.
The significance of subclinical hypothyroidism is
uncertain, other than the possibility of progression to frank
hypothyroidism.' Althou9h by definition there should be no
clinical features of hypothyroidism, symptoms such as
fatigue, dry skin, cold intolerance, constipation and muscle
cramps have been shown to occur twice as often in patients
with subclinical hypothyroidism.' Of patients given thyroxine
replacement, 50% showed a symptomatic improvement
compared with 12% of those on placebo. Improvements in
left ventricular function, lipoprotein abnormalities, short-term
memory, calculation speed and reaction time have been
reported in patients given thyroid hormone.~"
There are concerns that thyrOXine therapy in subclinical
hypothyroidism may aggravate coeXisting coronary artery
disease, with worsening of angina, or that it may precipitate
cardiac arrhythmias especially atrial fibrillation. I? It has also
been suggested that bone loss may be accelerated, perhaps
hastening the development of osteoporosis. 1J.1':' At present


















Positive predictive value (%) for:
Predicting hypothyroidism
Predicting thyroid dysfunction
Positive predictive value -; true positive
false positive.
Table V. Positive predictive value of depressed TSH le'Jels
Predicting hypothyroidism
Predicting thyroid dysfunction
Positive predictive value = true positive
false positive.
of the sUbjects on these agents had normal TSH
concentrations. There were 18 subjects on thyroxine
replacement therapy for hypothyroidism (spontaneous or
post-thyroidectomy). Corticosteroids (usually prednisone for
chronic chest disease) were being taken by 11 subjects.
Dopamine preparations were being used for treatment of
parkinsonism in 19 subjects, while 140 subjects were
receiving dopamine receptor-blocking agents, mostly
neuroleptics used for behaviour modification in patients with
dementia or chronic schizophrenia. The antihypertensive
agents, methyldopa and reserpine, which are known to
compete with or block the action of dopamine, were being
used by 45 subjects. Uthium and amiodarone were each
being taken by a single participant.
The positive predictive values of TSH in detecting thyroid
dysfunction or overt thyroid disease are shown in Tables IV
and V. The TSH appears to be a fairly reliable predictor of
thyroid dysfunction, but it is considerably less useful in
predicting overt thyroid disease. An elevated TSH level is a
far more useful indicator of thyroid dysfunction (inclUding
overt thyroid disease) than a depressed one.
This is the first published study of its kind to have been
conducted in South Africa. It was undertaken in 4 old-age
homes, 2 of which at the time of the stUdy were exclusively
for whites while the other 2 were for people of mixed
descent. At that time there were no similar facilities for
elderfy blacks. (Recent changes in the country have meant
that admission criteria of old-age homes have changed to
include people of all races, although full integration will take
some time to achieve.)
The stUdy population comprised residents of old-age
homes and not community-dwelling elderly. As a
consequence, they were probably more infinn on average
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that it alerts one to the possibility of the later development
of overt hypothyroidism_
Depressed serum TSH concentrations were indicative of
thyrotoxicosis in only 5 of 62 patients. In 3 this was due to
newly diagnosed hyperthyroidism (0.5% of the total study
population as opposed to 0.1 % in Parle et al. 's studl). A
further 2 were on excess thyroxine replacement, 1 for
spontaneous hypothyroidism and 1 following thyroidectomy.
Assays sensitive enough to distinguish between normal
and low concentrations of TSH allow the identification of a
group of patients WITh low TSH levels but no clinical
manifestations of hyperthyroidism and normal
concentrations of FT~ and FT3- These patients are
considered to have subclinical hyperthyroidism. Twenty-five
participants in this study satisfied these criteria, giving a
prevalence of 3.9% (25/640). The prevalence in other studies
has ranged from 5.5% to 12.4%. The observation of the
frequently transient nature of subclinical hyperthyroidism
was clearly demonstrated in 10 subjects (40%) in our study.
and in 60.6% elsewhere.6 Progression to overt
hyperthyroidism is not well recognised. This was confirmed
in this study where only 1 subject (4%) developed
thyrotoxicosis within 1 year.
It is now recognised that subclinical hyperthyroidism is an
independent risk factor for the development of atrial
fibrillation, those subjects with a TSH level of 0.1 ~U/ml or
less having a threefold greater chance of developing atrial
fibrillation than those whose TSH level is normal.1S
Subclinical hyperthyroidism may be accompanied by
features such as muscular weakness or neuromuscular
dysfunction, increase in the pulse rate, premature atrial
contractions and an increase in left ventricular mass and
contractHity.I&.11 Bone loss may be accelerated, with a
resultant decrease in bone density. la
There were 13 subjects with depressed serum TSH
concentrations who were considered biochemically
euthyroid, as evidenced by normal FT~ levels, but who had
reduced FT3 levels. The exact cause of this was not
determined. It is known that 5'-deiodinase activity decreases
with age, resulting in decreased formation of T3 , and this
may be at least partly responsible for this phenomenon. The
sick euthyroid syndrome might have been a cause of
decreased T3 levels in at least some of those with depressed
TSH levels, as they all had chronic medical problems·,
usually hypertension or cardiac failure. 1!UO
Approximately one-third of the subjects in this study were
receiving pharmacological agents reported to affect the
results of thyroid function tests,20 but biochemical evidence
of thyroid dysfunction was observed in only a small
percentage (25/235 = 10.6%) in this stUdy.
The value of the serum TSH concentration as a screening
test depends on what one is hoping to achieve. This study
demonstrates that the serum TSH concentration predicts
thyroid dysfunction 1.5 to 3 times more often than
biochemical disease. The utility of a raised TSH
concentration is greater than that of a depressed one, as
many subjects may have a TSH concentration of 0 and yet
be euthyroid. It is also apparent that the cut-off level used
has a significant effect on the usefulness of the test. A TSH
> 20 ~U/ml will correctly predict hypothyroidism 3 times
more often than a TSH > 5 ~Ulml. Similarly, a TSH of 0 is 3
times more likely to be indicative of hyperthyroidism than a
TSH < 0.4 ~U/ml.
In conclusion, thyroid dysfunction in this population of
elderly people had a prevalence of 11.2%, which had
hitherto been unrecognised in two-thirds [1.8%). This study
indicates that the TSH is reliable if used as a screening test
to predict thyroid dysfunction in elderly persons, but is less
valuable when used to predict biochemical thyroid disease.
An elevated TSH concentration is a better predictor of
thyroid dysfunction than a depressed one.
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